Multilevel cancer modeling in the clinical environment: Simulating the behavior of wilms tumor in the context of the SIOP 2001/GPOH clinical trial and the ACGT project

8th IEEE International Conference on BioInformatics and BioEngineering, BIBE 2008

Volumn , Issue , 2008, Pages

  Georgiadi, Eleni Ch ^a,b   Stamatakos, Georgios S ^a   Graf, Norbert M ^c   Kolokotroni, Eleni A ^a   Dionysiou, Dimitra D ^a   Hoppe, Alexander ^c   Uzunoglu, Nikolaos K ^a  

^a INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MECHANISMS; CHEMOTHERAPEUTIC AGENTS; CLINICAL DATA; CLINICAL ENVIRONMENTS; CLINICAL PRACTICES; CLINICAL TRIAL; DYNAMICS MODELS; IN-SILICO; MULTISCALE; NUMERICAL RESULTS; OPTIMAL TREATMENT; OPTIMIZATION SYSTEM; PATIENT SPECIFIC; RELATIVE IMPORTANCE; SOLID TUMORS; TRANSITION RATES; TUMOR CELLS; TUMOR GROWTH; TUMOR MODELS; TUMOR RESPONSE;

BIOINFORMATICS; CLARIFICATION; CONVERGENCE OF NUMERICAL METHODS; DYNAMICS; OPTIMIZATION; PATIENT TREATMENT;

TUMORS;

EID: 67549142863     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/BIBE.2008.4696759     Document Type: Conference Paper

References (19)

1. ACGT: Advancing Clinicogenomic Trials on Cancer (FP6-2005-IST- 026996), http://www.eu-acgt.org/
2. nd International Advanced Research Workshop on In Silico Oncology, Kolympari, Chania, Greece, 25-26 Sept. 2008, Ed. K. Marias and G. Stamatakos, pp. 36-38 (http://www.ics.forth.gr/bmi/2nd-iarwiso/)
3. G.S. Stamatakos, D.D. Dionysiou, E.I. Zacharaki, N.A. Mouravliansky, K.S.Nikita, N.K. & Uzunoglu, In silico radiation oncology: combining novel simulation algorithms with current visualization techniques, Proceedings of IEEE: Special Issue on Bioinformatics: Advances and Chalenges, 90(11), 1764-1777, 2002.
4. D. D. Dionysiou, G. S. Stamatakos, N.K. Uzunoglu, K. S. Nikita, A. Marioli, "A four-dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation," Journal of Theoretical Biology vol. 230, pp. 1-20, 2004
5. G. S. Stamatakos, V. P. Antipas and N. K. Uzunoglu, "A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide," IEEE Transactions on Biomedical Engineering, vol. 53, pp. 1467- 1477, 2006
6. G.S. Stamatakos, D.D. Dionysiou, N.M. Graf, N.A. Sofra, C. Desmedt, A. Hoppe, N. Uzunoglu, M. Tsiknakis, "The Oncosimulator: a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology," Proceedings of the 29th Annual International Conference of the IEEE EMBS, August 23-26, SuB07.1: 6628-6631, Lyon, France, 2007
7. Lodish D. Baltimore, A. Berk, S. Zipursky, P. Matsudaira, and J. Darnell, Molecular Cell Biology. New York: Scientific American Books, 1995, pp. 1247-1294.
8. Perez and L. Brady, Eds., Principles and Practice of Radiation Oncology.
9. G. Steel, Ed., Basic Clinical Radiobiology, 3rd ed. London, U.K.: Arnold, 2002, pp. 165-168, pp. 13, 52-63.
10. S.E. Salmon and A.C. Sartorelli "Cancer Chemotherapy", in Basic & Clinical Pharmacology, B.G.Katzung, ed. Lange Medical Books/McGraw-Hill, International Edition, 2001, pp.923-1044.
11. E. Groninger, T. Meeuwsen-de Boer, P. Koopmans, D. Uges, W. Sluiter, A. Veerman, W. Kamps, S. de Graaf. Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia. Pediatric Research vol. 52: pp. 113-118, 2002.
12. W.N. Dahl, R. Oftebro, E.O.Pettersen, T. Brustad, "Inhibitory and cytotoxic effects of Oncovin (Vincristine Sulfate) on cells of human line NHIK 3025," Cancer Res. vol. 36, pp. 3101-3105, 1976.
13. W.T.Beck, C.E.Cass, P.J.Houghton. "Microtubule-targeting anticancer drugs derived from plants and microbes: Vinca alkaloids, taxanes and epothilones," In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine, 5th Edition. Atlanta: American Cancer Society; 2000 pp. 680-698.
14. K.W. Wood, W.D. Cornwell, J.R. Jackson, " Past and future of the mitotic spindle as an oncology target," Current Opinion in Pharmacology vol. 1(4), pp. 370-377, 2001.
15. C. R. Pinkerton, B. McDermott, T. Philip, P. Biron, C. Ardiet, H. Vandenberg, and M. Brunat- Mentigny, "Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity," Cancer Chemother Pharmacol 22: 271-274, 1988.
16. H. Kobayashi, Y.Takemura, JF. Holland, T.Ohnuma, "Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukaemia cells, " Biochem. Pharmacol. vol. 55, pp. 1229-1234, 1998.
17. K.Sawada, K.Noda, H. Nakajima, N. Shimbara, Y.Furuichi, M. Sugimoto, "Differential cytotoxicity of anticancer agents in pre- and post- immortal lymphoblastoid cell lines," Biol Pharm Bull vol. 28, pp. 1202-1207, 2005.
18. G.J. Veal, M. Cole, J. Errington, A. Parry, J. Hale, A.D.J. Pearson, K.Howe, J.C.Chiholm, C.Beane, B.Brennan, F.Waters, A.Glaser, S.Hemsworth, H. McDowell, Y.Wright, K.ritchard- Jones, R.Pinkerton, G.Jenner, J.Nikolson, A.M.Elsworth, A.V.Boddy, and UKCCSG Pharmacology Working Groups, "Pharmacokinetics of Dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study group study," Clin Cancer Res vol. 11(16), pp. 5893-5899, 2005.
19. C.D.Scripture and W.D.Figg, "Drug interactions in cancer therapy," Nat Rev Cancer 6, pp. 546-558, 2006.